Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
0.530
+0.017 (3.37%)
At close: Jan 17, 2025, 4:00 PM
0.515
-0.015 (-2.81%)
After-hours: Jan 17, 2025, 7:37 PM EST
Company Description
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Ralph Schiess |
Contact Details
Address: 201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513 620 4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ralph Schiess Ph.D. | Interim Chief Executive Officer and Chief Science Officer |
| Karina M. Fedasz | Interim Chief Financial Officer |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Christian Bruhlmann | Chief Strategy Officer and GM of Europe |
| Dr. Donald L. Very Jr., Ph.D. | Senior Vice President of Commercial Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 424B3 | Prospectus |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 11, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 10, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 10, 2024 | 10-Q | Quarterly Report |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 15, 2024 | 424B4 | Prospectus |